Evidence map›Paper›PMID 42426152›Full record

ArticleEuropean journal of human genetics : EJHG2026

Copy number variant analysis by exome sequencing is an effective approach to optimize diagnostic yield for developmental disorders-the DDD-Africa study.

Nadja Louw, Prince Makay, Phelelani T Mpangase, Barry Shingwenyana, Zandisiwe Goliath, Thirona Naicker, Laura M Yates, Engela Honey, Gerrye Mubungu, Kris Van Den Bogaert and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Nadja Louw *Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa. nadja.louw@wits.ac.za.ORCID http://orcid.org/0009-0007-3716-8172
Prince Makay *Center for Human Genetics, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.ORCID http://orcid.org/0000-0002-2910-9590
Phelelani T MpangaseSydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-8280-8940
Barry ShingwenyanaDivision of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa.
Zandisiwe GoliathDivision of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa.
Thirona NaickerDepartment of Paediatrics, Medical Genetics, School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
Laura M YatesKwazulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa.
Engela HoneyDepartment of Biochemistry, Genetics and Microbiology, Faculty of Natural and Agricultural Science, University of Pretoria, Pretoria, South Africa.
Gerrye MubunguCenter for Human Genetics, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Kris Van Den BogaertCenter for Human Genetics, University Hospitals, University of Leuven, Leuven, Belgium.
Helen V FirthWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Matthew E HurlesWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0002-2333-7015
Prosper Lukusa TshiloboCenter for Human Genetics, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Koen DevriendtCenter for Human Genetics, University Hospitals, University of Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3651-2548
Amanda KrauseDivision of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0002-7157-0807
Nadia CarstensDivision of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0003-4754-7030
Aimé LumakaCenter for Human Genetics, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Zané LombardDivision of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0002-7997-2616

Funding

Deciphering Developmental Disorders in Africa (DDD-Africa) - Evaluating Clinical Exome Sequencing in an African SettingU01MH115483 · NIMH · WITS HEALTH CONSORTIUM (PTY), LTD · PI LOMBARD, ZANE · 2017 to 2021
$1.3M
U.S. Department of Health & Human Services | National Institutes of Health (NIH) 5U01HD114537U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) U01MH115483
6 · The paper itself

Abstract

Copy number variants (CNV) contribute significantly to the pathogenic variation associated with developmental disorders. CNV detection is often not included in standard exome sequencing (ES) analysis. Complementary methods such as chromosomal microarray are typically offered in diagnostic laboratories to diagnose pathogenic CNV. In this study, we aimed to develop an effective approach for incorporating CNV detection within our ES analysis process for the Deciphering Developmental Disorders in Africa (DDD-Africa) cohort. We analyzed ES data from 505 probands with a developmental disorder, applying a CNV detection approach that assessed data generated using the tools CANOES and XHMM. When available, parental ES data was used to assess inheritance patterns. We confirmed a diagnosis in 41/505 (8,1%) patients with 43 pathogenic CNV identified in the probands. There were 31 deletions and 12 duplications. Among the 26 probands with parental data, all identified CNV were de novo. The addition of CNV analysis to our ES analysis pipeline resulted in an 8.1% increase in diagnostic yield in the DDD-Africa cohort without additional laboratory cost. This offers a feasible approach which is likely to reduce analytical cost and is suitable for low- and middle-income countries where funding and resources for genomic medicine initiatives are limited.

Identifiers

PMID42426152

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.